Gilead Sciences, Inc. today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old ...

The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.

Krystal Biotech KRYS reported fourth-quarter earnings per share of $1.52, which beat the Zacks Consensus Estimate of $1.29 as ...

Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively ...

MUNICH, Germany, and BASILDON, UK I February 13, 2025 I LINDIS Biotech GmbH, a clinical stage biopharmaceutical company with a proprietary multi-specific ...

WHY EUROPE MUST ACT TO PROTECT ACCESS TO MEDICINESAmsterdam, 20 February 2025 New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are ...

DIA's Europe Annual Meeting, featuring discussions from top European health leaders, will be held March 18-20 in Basel.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli ® (pegcetacoplan) ...

Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 ...